Justin Hanes

TL;DR: The history of the development of PEGylated nanoparticle formulations for systemic administration is described, including how factors such as PEG molecular weight, PEG surface density, nanoparticle core properties, and repeated administration impact circulation time.

TL;DR: The tenacious mucus barrier properties that have precluded the efficient penetration of therapeutic particles are described and the design and development of new mucus-penetrating particles that may avoid rapid mucus clearance mechanisms are reviewed to provide targeted or sustained drug delivery for localized therapies in mucosal tissues.

TL;DR: The protective barrier properties of mucus secretions, how mucus affects the fate of orally administered nanoparticles, and recent developments in nanoparticles engineered to penetrate the mucus barrier are addressed.

TL;DR: A new type of inhalation aerosol, characterized by particles of small mass density and large size, permitted the highly efficient delivery of inhaled therapeutics into the systemic circulation.

TL;DR: It is demonstrated that large nanoparticles, if properly coated, can rapidly penetrate physiological human mucus, and they offer the prospect thatLarge nanoparticles can be used for mucosal drug delivery.